What is Global Hereditary Angioedema Therapeutic Market?
The Global Hereditary Angioedema Therapeutic Market is a specialized sector within the broader pharmaceutical industry. It focuses on the development, production, and distribution of therapies for Hereditary Angioedema (HAE), a rare and potentially life-threatening genetic condition characterized by episodes of severe swelling in various parts of the body. This market is driven by the need for effective treatments for HAE, which can significantly improve the quality of life for those affected by this condition. The market encompasses a range of therapeutic options, including drugs, biologics, and medical devices, all designed to manage and reduce the symptoms of HAE. The market's value is determined by the demand for these therapies, the cost of development and production, and the pricing strategies employed by pharmaceutical companies.
Intravenous, Subcutaneous, Oral in the Global Hereditary Angioedema Therapeutic Market:
The Global Hereditary Angioedema Therapeutic Market is segmented based on the route of administration of the therapies, which includes Intravenous, Subcutaneous, and Oral. Intravenous therapies are administered directly into the bloodstream, allowing for rapid and efficient delivery of the therapeutic agent. This method is often used for acute attacks of HAE, where rapid symptom relief is crucial. Subcutaneous therapies are injected under the skin and are typically used for long-term management of HAE. They offer the advantage of self-administration, allowing patients to manage their condition at home. Oral therapies are taken by mouth and are a convenient option for many patients. They can be used for both acute attacks and long-term management, depending on the specific drug and its mechanism of action. The choice of therapy depends on various factors, including the severity and frequency of the patient's HAE attacks, their overall health status, and their personal preferences.
Hospitals, Clinics, Others in the Global Hereditary Angioedema Therapeutic Market:
The Global Hereditary Angioedema Therapeutic Market serves a variety of healthcare settings, including Hospitals, Clinics, and Others. Hospitals are a major consumer of HAE therapies, as they often treat patients with severe and acute attacks of HAE. They require a range of therapeutic options to manage these cases effectively, from intravenous drugs for immediate symptom relief to long-term management strategies. Clinics, on the other hand, often focus on the long-term management of HAE. They provide patients with the necessary therapies and monitor their condition over time, adjusting treatment plans as necessary. Other settings, such as home healthcare and specialized HAE treatment centers, also utilize these therapies to provide comprehensive care for HAE patients.
Global Hereditary Angioedema Therapeutic Market Outlook:
Looking at the market outlook, the Global Hereditary Angioedema Therapeutic Market has shown promising growth. In 2023, the market was valued at US$ 2088.6 million and is projected to reach US$ 3050 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.1%. This growth is in line with the overall expansion of the global pharmaceutical market, which is expected to grow at a CAGR of 5% over the next six years, reaching a value of 1475 billion USD in 2022. The chemical drug market, a subset of the pharmaceutical market, is also expected to see growth, increasing from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. These trends indicate a positive outlook for the Global Hereditary Angioedema Therapeutic Market, reflecting the ongoing demand for effective HAE therapies and the continued investment in their development and production.
| Report Metric | Details |
| Report Name | Hereditary Angioedema Therapeutic Market |
| Accounted market size in 2023 | US$ 2088.6 million |
| Forecasted market size in 2030 | US$ 3050 million |
| CAGR | 5.1% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | BioCryst Pharma, Ionis Pharma, Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies, KalVista Pharma |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
